App
International Edition

Tuesday

February, 28, 2017

Breaking News, World News and Taiwan News.
About Us
Subscribe
Advertise
Contact Us

Roche's breast cancer franchise given boost by postive trial data

LONDON--Roche, the world's biggest maker of cancer drugs, got a boost on Monday as results of trials that will protect sales of its breast cancer drug Herceptin coincided with data showing a new drug in the franchise helped patients live longer.

Two trials on Roche's blockbuster Herceptin wiped out a risk that they could have indicated a shorter period of treatment than the current recommendation of one year — a finding that could have cost up to US$1.5 billion in sales.

A third trial comparing Roche's experimental drug TDM-1 with a standard cocktail of drugs in patients with an aggressive form of advanced breast cancer showed the new drug helped patients live more than five months longer.

TDM-1, or trastuzumab emtansine, is an "armed antibody" drug being developed by Roche and Immunogen as a successor to Herceptin, which could be exposed to so-called "biosimilar" generic competition in Europe from around 2015.

Write a Comment
CAPTCHA Code Image
Type in image code
Change the code
 Receive our promos
 Respond to this email
MOST POPULAR OF THIS SECTION
Subscribe  |   Advertise  |   RSS Feed  |   About Us  |   Career  |   Contact Us
Sitemap  |   Top Stories  |   Taiwan  |   China  |   Business  |   Asia  |   World  |   Sports  |   Life  |   Arts & Leisure  |   Health  |   Editorial  |   Commentary
Travel  |   Movies  |   TV Listings  |   Classifieds  |   Bookstore  |   Getting Around  |   Weather  |   Guide Post  |   Student Post  |   Terms of Use  |   Sitemap
  chinapost search